54 results about "Halofuginone" patented technology

A composition for treating hepatic fibrosis and a method of using and manufacturing the composition are provided. The composition includes a quinazolinone derivative, preferably Halofuginone.

An effective treatment for skin disorders characterized by abnormal skin cell behavior, including a pharmaceutically effective amount of Halofuginone. Skin disorders which can be treated include keloids, hypertrophic scars, psoriasis, acne, seborrhea and alopecia. Halofuginone can reduce or eliminate clinical symptoms of these disorders, as well as substantially prevent the formation of keloids and hypertrophic scars.

The invention discloses a method for preparing a halofuginone intermediate shown in a formula D or E. The method comprises the following steps of: (1) dropwise adding solution of a compound F into benzyl chloroformate solution, and performing Van Braun reaction to obtain a compound E; and (2) performing Claisen rearrangement reaction on the compound E obtained in the step (1). By the method, the Van Braun reaction can be completely performed, the using amount of benzyl chloroformate is reduced, the efficiency of the reaction is improved, and a 2-bit product can be selectively obtained in the subsequent Claisen rearrangement reaction. In the better embodiment of the invention, the operation process is simplified by a one-pot method, the using amount of solvents is reduced, the selectivity is improved, the cost of the reaction is reduced, the pollution to the environment is reduced, and good conditions are created for mass production of halofuginone.

A medical device comprising halofuginone is provided. The medical device is adapted for implantation or insertion into a blood vessel and it provides a cumulative, in vivo, 14 day release that lies between 0.02 μg and 0.2 μg of halofuginone per mm2 of stent surface area.

The present invention relates to biocompatible polymeric delivery systems for controlled or sustained release of quinazolinone derivatives, including the compound halofuginone. In particular the invention relates to a polymeric delivery system comprising biocompatible polymeric beads having a two-phase core and shell structure, or polymeric films, beads or complexes that provide local sustained release of the pharmacological agent.

The invention provides a preparation method of a halofuginone molecularly-imprinted solid-phase extraction small column and an application and relates to the field of analytical chemistry. The preparation method comprises the following steps of: taking halofuginone as a template molecule, dissolving the template molecule into a porogen and adding a functional monomer at a low temperature for prepolymerization; then, mixing according to the molar ratio of the template molecule: the functional monomer: a cross-linking agent of 1:3-6:15-30, and preparing molecularly-imprinted polymer micro-spheres in a manner of initiated polymerization at a low temperate by adopting a suspension polymerization method and filling the rinsed, sieved, eluted and dried micro-spheres in an empty column tube of the solid-phase extraction column by adopting a wet process; and later, using the micro-spheres rinsed by acetone and methanol in sequence into selective adsorption, enrichment and purification of the halofuginone remained in animal derived foods. Compared with the existing solid-phase extraction column, the halofuginone molecularly-imprinted solid-phase extraction column prepared by the invention has the characteristics of strong specificity, convenience and simplicity in preparation, good recognition performance, low cost, easiness for realization of required instruments and reaction conditions and the like.

The present invention relates to acid stabilized compositions containing as an active ingredient a quinazolinone derivative, preferably halofuginone or a pharmaceutically acceptable salt of halofuginone. More particularly the present invention relates to use of an acid for improving the stability of a topical, parenteral or oral composition containing quinazolinone derivatives as an active ingredient, preferably halofuginone. Surprisingly, even dry solid tablet dosage forms showed improved stability by addition of an acidic component.

The invention relates to a synthetic method for halofuginone and an intermediate of the halofuginone. The reaction formula is shown in the description, wherein R1 is one selected from the group consisting of methyl, ethyl, n-propyl, isopropyl and t-butyl; R2 is one selected from the group consisting of methyl and ethyl; and R3 is one selected from the group consisting of methoxyformyl, ethoxyformyl, tert-butoxyformyl, benzyloxyformyl, trichloroethoxyformyl and benzyl. The synthetic method provided by the invention has the advantages of a simple process, low costs, few by-products in the synthetic process, a simple purification process, no need of column chromatography purification, a high product yield, less impurities, high purity, and controllable product quality, easily meets ICH declaration requirements and can be used for industrial production of the halofuginone.

According to the present invention compositions and methods are provided to prevent the pathogenic aspects of tissue trauma while preserving normal tissue repair mechanisms, based on the fact that these molecules abrogate the cascade of damage initiated by tissue trauma, while maintaining this the requisite healthy extracellular matrix economy. The composition for regulating the extracellular matrix economy, comprise a pharmaceutically effective amount of an effector in combination with a pharmaceutically acceptable carrier. Preferably, the effector is a quinazolinone derivative. More preferably, the quinazolinone derivative is a member of a group having formula (I), wherein R1 is a member of the group consisting of hydrogen, halogen, nitro, benzo, lower alkyl, phenyl, and lower alkoxy; R2 is a member of the group consisting of hydroxy, acetoxy, and lower alkoxy, and R3 is a member of the group consisting of hydrogen and lower alkenoxy; and pharmaceutically acceptable salts thereof; and n is either 1 or 2. Most preferably, the effector is Halofuginone and pharmaceutically acceptable salts thereof.

The invention relates to a preparation method of cis-2-(2-chloropropene)-3-hydroxyl piperidine with optical activity and application of cis-2-(2-chloropropene)-3-hydroxyl piperidine in preparing halofuginone. The preparation method of cis-2-(2-chloropropene)-3-hydroxyl piperidine with optical activity comprises the following steps: (1) in a first organic solvent, performing a salt forming reactionon racemic cis-2-(2-chloropropene)-3-hydroxypiperidine and dibenzoyltartaric acid or a derivative thereof so as to generate precipitate, recrystallizing the precipitate so as to obtain a chiral composite salt; and (2) in a second organic solvent, neutralizing the chiral composite salt to alkaline by using an alkali water solution, so as to obtain the cis-2-(2-chloropropene)-3-hydroxyl piperidinewith optical activity. The method is cheap in raw material, easy in raw material obtaining, simple in preparation process, small in product impurity and free of column chromatography purification, andin addition, on-scale production preparation of halofuginone with a high optical purity can be achieved.

The invention relates to compound powder for treating fish sporozoan disease and a preparation method thereof. The compound powder comprises the following medicinal components in parts by weight: 5 to 10 parts of turmerone, 10 to 20 parts of astragalus polysaccharide, 3 to 5 parts of laccocephalum mylittae, 1 to 5 parts of halofuginone, 1 to 5 parts of plant flavonoid, 2 to 5 parts of betel nut, 15 to 20 parts of radix sophorae flavescentis, and 40 to 50 parts of glucose. The preparation method comprises the following steps of: crushing turmerone, astragalus polysaccharide, laccocephalum mylittae, halofuginone, plant flavonoid, betel nut, radix sophorae flavescentis, and glucose; screening by using a 60-mesh screen; weighing the components in parts by weight above; and uniformly mixing at normal temperature. The compound powder is clear in components, stable in effect, convenient to use, high in bioavailability, can be directly orally taken, is not influenced by weather and environment conditions, and has the effects of quickly recovering fish body health and appetite, decreasing sporozoan, controlling death of fish caused by sporozoan, and recovering fish to normal quickly after being taken.

The invention relates to a traditional Chinese medicine composition for anticoccidial, stopping bleeding, enriching the blood, antisepticising and anti-inflammatory and a preparation thereof. The main effective components of the traditional Chinese medicine composition are arteannuin and halofuginone which are liposoluble substances with small polarity and hard to be extracted by water; in order to ensure the anticoccidial function of the medicine, the arteannuin and halofuginone are respectively extracted by petroleum ether and ethanol to obtain effective components at first, then combined together and extracted by water to obtain a filtrate; the filtrate is decompressed, concentrated, dried and added with alcohol extracts when palletized; after the whole pallets are dried, the granule medicine is obtained. The traditional Chinese medicine composition is palletized with main components of a monarch medicine; by improving quality standard, improving the technique, enhancing the in-process quality control, screening authentic medicinal herbs, stabilizing product quality, the Chinese medicine composition has low cost, good effect in anticoccidial, stopping bleeding, enriching the blood, antisepticising and anti-inflammatory and strong market competitive power.

The invention belongs to the technical field of chemical synthesis, and relates to a 3-hydroxy-2-piperidineamide framework febrifugine (halofuginone) and a preparation method thereof. The compound hasa structure represented by formula (I) shown in the description. The preparation method of the invention has the advantages of simplicity in operation, simple route and high yield, and all reagents used in the invention are common reagents, so the method is suitable for large-scale preparation; and the obtained target product can be used for the diversity-oriented synthesis research of various natural products with important physiological activities.

The invention provides a deoxidized halofuginone compound. A structural formula of the deoxidized halofuginone compound is as shown in the specification, wherein R1 refers to a halogen radical or hydrogen; R2 refers to hydrogen, a halogen radical, C1-C3 alkyl, C1-C3 alkoxy or trifluoromethyl; R3 refers to hydrogen, a halogen radical, C1-C3 alkyl, C1-C3 alkoxy or trifluoromethyl; X1 or X2 refers tonitrogen or carbon; Y refers to hydrogen, hydroxyl or carbonyl. The synthetic deoxidized halofuginone compound with piperidine as a raw material has advantages of cheapness and easiness in acquisition of the raw material, simplicity and easiness in operation of a synthesis method, high yield and product stability. The deoxidized halofuginone compound has great inhibiting effects on Gram positive(Gram<+>) and Gram negative (Gram<->) and has a promising application prospect in treatment of human and poultry bacterial infection.

The present invention relates to pharmaceutical compositions comprising as an active ingredient an isolated, chirally pure D-enantiomer of the quinazolinone derivative halofuginone having increased therapeutic activity and decreased side effects compared to the corresponding racemic mixtures, the composition being substantially free of the L-enantiomer and useful in the treatment of diseases and disorders associated with fibrotic conditions or cell proliferation.

The invention belongs to the field of chemical synthesis, and relates to a preparation method of a key chiral intermediate trans-3-hydroxy-2-allyl piperidine of febrifugine and halofuginone and analogues of the chiral intermediate. The technical route of preparing the trans-3-hydroxy-2-allyl piperidine and the analogues of the trans-3-hydroxy-2-allyl piperidine provided by the invention has simpleoperation, concise route and high yield, and the used reagents are all common reagents. The costs of the trans-3-hydroxy-2-allyl piperidine and the analogues of the trans-3-hydroxy-2-allyl piperidineprepared by the method are obviously reduced; the preparation of a 100-gram grade can be conveniently realized in a laboratory; the preparation method can be suitable for large-scale preparation; andthe febrifugine and halofuginone can be obtained through simple transformation of the obtained target compound.

The invention relates to the field of drug synthesis, and discloses a preparation method of a halofuginone intermediate trans-N-carbobenzoxy-(3-hydroxy-2-piperidyl)-2-acetone. In the preparation method, amino substituted valeraldehyde and a thiazole sulfoxide compound are used as raw materials for the first time, and are subjected to a Misflow-Evans rearrangement reaction; and then the trans-N-carbobenzoxy-(3-hydroxy-2-piperidyl)-2-acetone as shown in a formula I is prepared in the specification under the catalysis of lewis acid. According to the preparation method of the halofuginone intermediate trans-N-carbobenzoxy-(3-hydroxy-2-piperidyl)-2-acetone, provided by the invention, the yield is relatively high, and the quality is stable. According to the technical scheme, a new route reference is provided for the synthesis of the trans-N-carbobenzoxy-(3-hydroxy-2-piperidyl)-2-acetone, and the reduction of pyridine is avoided, so that the defect that an expensive Rh / Al2O3 metal catalyst needs to be used is overcome.

The invention discloses a compound febantel chewable tablet for dogs and cats. The active ingredients of the chewable tablet include praziquantel, pyrantel, febantel and halofuginone. The chewable tablet overcomes the characteristic of poor palatability of traditional tablets, can enable dogs and cats to chew drugs fully, and can ensure that the drugs are fully absorbed and good efficacy can be brought into play. The tablet provided in the invention comprises, by mass: 10%-20% of febantel, 5%-10% of praziquantel, 15%-25% of pyrantel, 5%-10% of halofuginone, 30%-50% of a filling agent, 0.5%-3% of a binder, and 5%-15% of a flavoring agent. The preparation process of the chewable tablet provided in the invention is simple, and can prepare the product with good taste and stable quality, thus being suitable for industrialized production.

The present invention relates to compositions containing quinazolinones. More particularly, the present invention relates to a composition for treatment renal fibrosis, comprising as active ingredient a quinazolinone derivative as herein defined. The currently preferred embodiment is halofuginone, which is now show to slow or prevent progression of renal fibrosis in vivo, thereby preventing end-stage renal failure.

An effective treatment for skin disorders characterized by abnormal skin cell behavior, including a pharmaceutically effective amount of Halofuginone. Skin disorders which can be treated include keloids, hypertrophic scars, psoriasis, acne, seborrhea and alopecia. Halofuginone can reduce or eliminate clinical symptoms of these disorders, as well as substantially prevent the formation of keloids and hypertrophic scars.

The present invention provides compositions and methods for improving the effectiveness of anti-tumor treatments. The compositions of the present invention comprise quinazolinones, specifically halofuginone. In currently preferred embodiments the compositions and methods of the present invention improve the effectiveness of radiation therapy and chemotherapy, and concomitantly alleviate or prevent the damage induced by radiation therapy.

An immune composition for use, via topical administration, in eliciting Th2 or regulatory T cell-mediated immune responses specific to H. pylori. The immune composition, free of both liposaccharides and mammalian proteins, contains a whole-cell H. pylori lysate, and optionally, a vitamin D compound, halofuginone, or a mixture thereof as the sole adjuvant.

The invention discloses a compound niclosamide chewing tablet used for dogs and cats. The active components of the chewing tablet comprise praziquantel, pyrantel, niclosamide and halofuginone. The chewing tablet overcomes a disadvantage of poor palatability of traditional tablets, allows the dogs and the cats to fully chew the medicine, and guarantees full adsorption of the medicine and exertion of good medicine effects. The tablet provided by the invention comprises following components by weight: 10-20% of the niclosamide, 5-10% of the praziquantel, 15-25% of the pyrantel, 5-10% of the halofuginone, 30-50% of a filling agent, 0.5-3% of an adhesive and 5-15% of a corrigent. The chewing tablet is simple in preparation process, good in product taste, stable in product quality, and suitable for industrial production.

The invention relates to a traditional Chinese medicine composition for anti-coccidial, hemostatic and blood-replenishing, anti-bacterial and anti-inflammation for chickens and a preparation method thereof. Soluble substances are difficult to extract with water. In order to ensure the anti-coccidial effect of the drug, Qinghao and Changshan use petroleum ether and ethanol to extract the active ingredients respectively, and then combine them for water extraction. The water extract is concentrated under reduced pressure, dried, and granulated. When adding the alcohol extract, the whole grain is dried to obtain the granule. The traditional Chinese medicine composition uses the main ingredients of monarch medicine to make granules, improves the quality standard, improves the process, strengthens the quality control process, screens authentic medicinal materials, stabilizes product quality, and is low in cost. The curative effect of chicken anti-coccidial, hemostasis and blood enrichment, antibacterial and anti-inflammatory is good. , with strong product market competitiveness.

An inhibitor of adhesion formation which can be used to prevent adhesions within the abdominal cavity, particularly following surgical intervention, trauma or inflammation in the area is disclosed. Specifically, the most preferred compound of the present invention. Halofuginone, can be used to prevent collagen deposition from occurring within the peritoneum after surgical intervention, thereby inhibiting adhesion formation. Halofuginone, and related compounds, are useful in the prevention and treatment of both inflammatory and surgically induced adhesions, and in the treatment of congenital adhesions.

The instant invention relates to the prevention of recurrence of urethral stricture after a conventional treatment. Compositions applicable to the prevention of recurrence of urethral stricture after as conventional treatment, including a pharmaceutically effective amount of halofuginone, are disclosed. Urethral stricture, as common disease, appears secondary to urethritis, urethral infection, urethral inflammation, urethral instrumentation, urethral catheterization, urethral trauma, urethral surgery and all types of urethral lesions. Conventional treatments by internal urethrotomy, urethral dilatation or surgical urethroplasty are available and can cure urethral stricture, but with a relatively high rate of recurrence of the stricture. Halofuginone can prevent the recurrence of urethral stricture after conventional treatment via internal urethrotomy, urethral dilatation or surgical urethroplasty.

The invention belongs to the technical field of feed additives, and discloses an anti-coccidiosis feed additive as well as a preparation method and application thereof, and the additive comprises the following components: halofuginone, callicarpa nudiflora and gynostemma pentaphylla, further comprises radix bupleuri and astragalus polysaccharide. The halofuginone has an excellent coccidiosis killing effect, the callicarpa nudiflora is added to be compatible with the halofuginone, main components of the callicarpa nudiflora comprise flavone and part of terpenoids, and the callicarpa nudiflora has the repairing and intestinal health maintaining effects of stopping bleeding, diminishing inflammation, astringing and the like; gynostemma pentaphylla is added, so that not only nutritional substanes can be provided, but also the effect of improving immunity and treating enteritis is achieved; through compatibility of the three components, the occurrence probability of enteritis caused by coccidiosis can be reduced, and the growth speed and the survival rate of chickens are increased.

The invention belongs to the technical field of chemical synthesis, and relates to a tetrahydropyrrolooxazinone and piperidino-oxazinone compounds and a preparation method thereof. The compound containing an oxazinone skeleton is prepared and has a wide range of biological activities such as weeding, insect killing, sterilization, inflammation diminishing, non-nucleoside reverse transcriptase inhibition, phosphodiesterase inhibition, antithrombotic activity, analgesia and the like, is also a core skeleton compound for preparing halofuginone and halofuginine with antimalarial and anticancer activities and the like, and is of great significance to research and development of novel pesticides. The preparation method disclosed by the invention has the characteristics of simple reaction conditions, high selectivity and capability of carrying out large-scale preparation.